title: Therapeutic options in malignant mesothelioma.
abstract: No significant advances have been made in the treatment of diffuse malignant mesothelioma in the past 12 months. For fit patients with early disease (stage I), radical surgery remains the best option, but doubt remains concerning optimum adjuvant therapy. A collaborative approach with multicentre trials of standardized treatment protocols is essential if any progress is to be made in the future.
authors.affiliation: University Hospital of Wales, College of Medicine, Cardiff, UK.
authors.forename: P
authors.initials: P
authors.lastname: Moreno de la Santa
authors.forename: E G
authors.initials: EG
authors.lastname: Butchart
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007372:Interferons / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D008654:Mesothelioma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009367:Neoplasm Staging; D010166:Palliative Care
chemical_list: D000970:Antineoplastic Agents; D007372:Interferons